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Abstract 
 
The sodium–glucose co-transporter 2 (SGLT2) inhibitors 
have proven effective in glycemia control in patients with type 2 
diabetes (T2D) by increasing urinary glucose excretion. 
However, the beneficial effects of SGLT2 inhibition extend 
beyond glycemic control, with new studies demonstrating 
beneficial effects that lead to improved cardiovascular (CV) 
(cardioprotection) and renal outcomes (renoprotection) in 
patients with T2D. Pivotal CV outcomes trials have 
demonstrated a 27-35% reduction in heart failure (HF) 
hospitalizations in patients with T2D. Importantly, a variety of 
pleiotropic effects of these new agents have been identified that 
include, but are not limited to, anti-atherosclerotic, anti-
inflammatory, and anti-oxidant effects, decreased vascular 
stiffness and improved endothelial function, weight loss, 
reduction in sympathetic activity and in cardiac 
arrhythmogenesis. Ongoing studies are investigating these 
actions in patients with and without diabetes. Such results, if 
positive, may lead to a paradigm shift in the management of CV, 
renal and even other diseases beyond diabetes. Rhythmos 
2020;15(1):1-5.  
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Abbreviations: CKD = chronic kidney disease; CV = 
cardiovascular; HF = heart failure; HFpEF = heart failure with 
preserved ejection fraction; HFrEF = heart failure with reduced 
ejection fraction; SGLT2 = sodium–glucose co-transporter 2; 
T2D = type 2 diabetes (mellitus)  
  
Introduction 
 
The sodium–glucose co-transporter 2 (SGLT2) 
inhibitors (gliflozins), empagliflozin, canagliflozin, 
dapagliflozin, ertugliflozin (all four FDA approved), and 
sotagliflozin (only EU approved) have proven to be 
effective in glycemia control in patients with type 2 
diabetes (T2D).1 SGLT2 inhibition increases urinary 
glucose excretion, decreasing blood glucose levels. 2   
However, the beneficial effects of SGLT2 inhibition 
extend beyond glycemic control, with new studies 
demonstrating that inhibition of renal glucose reabsorption 
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reduces blood pressure, ameliorates glucotoxicity and 
confers hemodynamic effects that lead to improved 
cardiovascular (CV) and renal outcomes in patients with 
T2D.3-5 Pivotal CV outcomes trials (EMPA-REG 
OUTCOME, CANVAS, DECLARE-TIMI 58) for the first 
three agents have demonstrated 13-38% relative risk 
reduction in CV-related deaths vs placebo (empagliflozin, 
canagliflozin), and a 27-35% reduction in heart failure 
(HF) hospitalizations (empagliflozin, canagliflozin, 
dapagliflozin).6-8   
These pleiotropic effects extend to a wide spectrum of 
actions that include weight loss induced initially by 
osmotic diuresis and later by reduction of fat mass; 
improved vascular stiffness and endothelial function; 
reduction in sympathetic activity and other effects 
discussed below and also mentioned in Table 1.  
 
Cardioprotective Effects 
 
Improved CV Outcomes. The SGLT2 inhibitor 
empagliflozin reduced CV mortality by 38% and HF 
hospitalizations by 35% in diabetic patients.6 
Canagliflozin reduced CV mortality by 13%, while it 
reduced the rate of hospitalization for HF by 33%.7 
Dapagliflozin conferred a 17% lower rate of CV death or 
hospitalization for HF, which reflected a 27% lower rate of 
hospitalization for HF.8 A recent meta-analysis of 42 trials 
with a total of 61,076 patients with T2D showed that 
compared with the control treatment, SGLT2 inhibitor 
treatment was associated with a reduction in the incidence 
of major adverse CV events (odds ratio-OR = 0.86, 
P < .0001), myocardial infarction (OR = 0.86, P =0 .001), 
CV mortality (OR = 0.74, P < 0.0001) and all-cause 
mortality (OR = 0.85, P <0 .0001).9   
Heart Failure. As mentioned, pivotal CV outcomes 
trials (EMPA-REG OUTCOME, CANVAS, DECLARE-
TIMI 58) demonstrated a 27-35% reduction in HF 
hospitalizations in patients with T2D.6-8 A recent meta-
analysis of the results in patients included in randomized 
controlled trials (RCTs) (N=34,322), observational studies 
(N=15,36,339), and both (N=15,70,661) demonstrated a 
significant decrease in HF hospitalizations (OR 0.70, 0.64, 
0.66, respectively, all p=0.000) with SGLT-2 inhibitors 
compared to placebo or other anti-diabetes drugs in 
T2DM.10 A significant benefit in HF hospitalizations (OR 
0.68, p=0.000) is also observed in patients with established 
HF (N=3891) in sub-group meta-analysis of RCTs.  
Importantly, a most recent report of the DAPA-HF 
trial, which included patients with NYHA II-IV HF with 
reduced (<40%) ejection fraction (HFrEF), randomized to 
dapagliflozin (n=2373) or placebo (n=2371), indicated that 
over a median of 18.2 months, the primary outcome, a 
composite of HF or CV death, was reduced by 
dapagliflozin by 26% (P<0.001), a first worsening HF 
event by 30%, CV death by 18% and total death by 17%.4 
Findings in patients with diabetes were similar to those in 
patients without diabetes. The frequency of adverse events 
related to volume depletion, renal dysfunction, and 
hypoglycemia did not differ between treatment groups. 
According to the recent results of the DEFINE-HF 
trial, in patients with HFrEF, use of dapagliflozin over 12 
weeks did not affect mean NT-proBNP but increased the 
proportion of patients experiencing clinically meaningful 
improvements in HF-related health status or natriuretic 
peptides.11 Results were consistent among patients with or 
without T2D. The authors concluded that benefits of 
dapagliflozin on clinically meaningful HF measures 
appear to extend to patients without diabetes. Similarly, the 
DAPA-HF trial showed that among patients with HFrEF, 
the risk of worsening HF or death from CV causes was 
lower among those who received dapagliflozin than among 
those who received placebo, regardless of the presence or 
absence of T2D.4   
Several mechanisms have been put forward to explain 
the benefits of SGLT-2 inhibitors in diabetic patients with 
HF, which also raise the possibility of using these drugs as 
therapies not only in the prevention of HF, but also for the 
treatment of patients with established HF regardless of the 
presence or absence of diabetes.12, 13  Ongoing dedicated 
HF trials will further shed light on the merits of SGLT-2Is 
in patients with established HF with or without T2D. 
Ischemia/Myocardial infarction. As mentioned, a 
recent meta-analysis of 42 trials (N=61,076) showed that 
compared with the control, SGLT2 inhibitor treatment in 
diabetic patients was associated with a reduction in 
myocardial infarction by 14% (P =0 .001). 9   
A cytoprotective effect, including protection against 
myocardial ischemia/reperfusion injury has been 
suggested by animal studies. Langendorff-perfused hearts, 
from diabetic and nondiabetic rats, fed long-term for 4 
weeks with canagliflozin, had lower infarct sizes.5 By 
contrast, direct treatment of isolated nondiabetic rat hearts 
with canagliflozin, solubilized in the isolated Langendorff 
perfusion buffer, had no impact on infarct size. This latter 
study demonstrates that the infarct-sparing effect of long-
term treatment with canagliflozin results from either a 
glucose-independent effect or up-regulation of cardiac 
prosurvival pathways. These results further suggest that 
SGLT2 inhibitors could be repurposed as novel 
cardioprotective interventions in high-risk CV patients 
irrespective of diabetic status. 
 
Renoprotective effects 
 
The results of studies in non-diabetic chronic kidney 
disease (CKD) models suggest that SGLT2 inhibitors 
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could also have a direct beneficial effect on the kidney, 
which would be independent of the glycemic and blood 
pressure control.3 Canagliflozin 100 or 300 mg/d, 
compared with glimepiride, slowed the progression of 
renal disease over 2 years in patients with T2D; 
importantly, canagliflozin conferred renoprotective effects 
independently of its glycemic effects.14   
The renoprotective effects of SGLT2 can also be 
ascribed to natriuresis resulting from inhibition of sodium 
and glucose reabsorption.3 An increased sodium delivery 
to the macula densa activates the tubuloglomerular 
feedback that leads to afferent arteriole vasoconstriction 
and a reduction in intraglomerular pressure. Interestingly, 
a pattern of change in renal function similar to that 
observed with angiotensin converting enzyme (ACE) 
inhibitors or angiotensin receptor blockers (ARBs) has 
been demonstrated for SGLT2 inhibitors, where a short-
term initial decrease of glomerular filtration rate is 
followed by stabilization over time, which appears to be 
reversible upon discontinuation of the drug.15 Other 
plausible mechanisms that have been proposed to 
contribute to renoprotection conferred by SGLT2 
inhibitors are blood pressure lowering, weight loss, 
amelioration of the volume overload and glycemic control 
itself. However, it is still not clear whether these drugs also 
exert direct protective effects on the kidney.  
 
Reduction of Sympathetic Overactivity 
 
It has been suggested that SGLT2 inhibitors reduce 
central sympathetic overactivity, probably by suppressing 
renal afferent signaling to the brain.16  An attenuation of 
sympathetic activity is deduced as no rise of heart rate is 
detected despite reductions in blood pressure and plasma 
volume. This effect has been demonstrated in experimental 
and clinical data, shown to occur in key target organs such 
as the heart and the kidneys.17   
 
Weight Loss 
 
Several studies support the concept that SGLT2 
inhibitors can be effective as adjuvant weight loss therapy 
when given together with agents that reduce food intake.18  
In overweight and obese subjects without diabetes, 
canagliflozin significantly reduced body weight compared 
with placebo and was generally well tolerated.19   
 
Pleiotropic Effects and Potential Mechanisms of 
Cardiovascular and Renal Protection 
 
 As mentioned, several pleiotropic effects on the heart, 
kidney, vessels, autonomic nervous system, and elsewhere 
and various potential mechanisms have been suggested to 
explain the cardioprotective and renoprotective effects of 
SGLT-2 inhibitors (Table 1). 1, 20, 21 Among others, anti-
atherosclerotic, anti-inflammatory, and anti-oxidant 
effects, decreased vascular stiffness and improved 
endothelial function have been proposed.22  Hemodynamic 
effects involving reduction in blood pressure and afterload, 
natriuresis-related intravascular volume contraction, and 
an osmotic diuresis have also been considered as potential 
mechanisms for the beneficial effects in patients with heart 
failure.23 SGLT2 inhibitors can also inhibit cardiac 
sodium-hydrogen exchanger (isoform 1) leading to 
improvement in cardiac injury and reduction of infarct 
size, hypertrophy, and fibrosis independently of their 
effects on sodium reabsorption or blood pressure; they can 
also inhibit renal sodium-hydrogen exchanger (isoform 3) 
leading to reduction of sodium reabsorption in the 
proximal tubule.24  Other factors that may be involved in 
CV protection may relate to plasma volume contraction–
mediated decreases in myocardial stretch contributing to 
reduced cardiac arrhythmogenesis, several metabolic 
effects (such as improved cardiac mitochondrial function 
and fuel energetics, decrease in body weight, decrease in 
uric acid and triglycerides and an increase in HDL 
cholesterol), and hormonal effects, such as increased 
glucagon release.25  An experimental study indicated that 
empagliflozin causes direct pleiotropic effects on the 
myocardium by improving diastolic stiffness and hence 
diastolic function; these effects were independent of 
diabetic conditions. 26 As mentioned, a reduction of 
sympathetic overactivity by SGLT-2 inhibitors has also 
been suggested as a cardioprotective mechanism.16  
Nevertheless, significant knowledge gaps remain in this 
field which investigators are now beginning to explore; 
ongoing and future trials may aid in this direction.  
 With regards to the renoprotective effects of SGLT-2 
inhibitors, several beneficial actions have been enlisted; 
blood pressure lowering even in the presence of CKD, 
reduced endothelial dysfunction and arterial stiffness; 
improved metabolic profile (decrease in weight and 
HbA1C); improved oxygenation of tubular cells and 
increased hematocrit; decreased albuminuria; optimized 
intravascular volume; decreased intraglomerular pressure; 
improved CV function that maintains renal perfusion. 27  
 
Side-Effects 
 
In the context of an emerging widespread optimism 
often reaching enthusiasm about the potential of these new 
antihyperglycemic agents with their pleiotropic effects 
demonstrated beyond their glycemic effects, one needs to 
be vigilant about their potential side-effects.28, 29  These 
harmful effects include euglycemic keto-acidosis which is 
a life-threatening condition requiring urgent hospitaliza-
tion; acute kidney injury has also been reported; serious 
urinary tract infections may occur, as well as genital 
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mycotic infections; an increased risk for lower limb 
amputation has been observed in patients receiving 
canagliflozin; these agents may increase the risk of 
hypoglycemia when used in combination with insulin or 
an insulin secretagogue; dose-related increases in LDL-
cholesterol have also been encountered.28, 29   
 
Table 1. Pleiotropic Effects of SGLT-2 Inhibitors 
Beyond the Anti-Hyperglycemic Effects 
 
● BP/afterload reduction by natriuresis and osmotic 
diuresis and consequent plasma volume reduction  
● Improved CV function maintains renal perfusion 
● BP lowering even in the presence of CKD  
● Decrease in intraglomerular pressure thus attenuating 
albuminuria  
● Anti-atherogenic effects 
● Cytoprotective effect, including protection against 
myocardial ischemia/reperfusion injury 
● Anti-inflammatory / anti-oxidant / anti-fibrotic effects 
● Improved endothelial function/Reduced arterial stiffness 
● Inhibition of sodium-hydrogen exchanger isoform 3 in 
heart/vasculature and isoform 1 in kidney leading to 
attenuation of cardiac injury, hypertrophy, and fibrosis 
independently of their effects on sodium reabsorption or 
BP 
● Metabolic effects: decreased triglycerides/uric 
acid/HbA1C, increased HDL, weight loss 
● Improved mitochondrial function and fuel energetics  
● Reduced arrhythmogenesis  
● Hormonal effects: increased glucagon release 
● Increased erythropoietin levels with increase in 
hematocrit improving O2 transport to heart and kidneys 
● Reduced SNS activity  
______________________________________________ 
BP = blood pressure; CKD = chronic kidney disease; CV = 
cardiovascular; SGLT-2 = sodium–glucose co-transporter 2; 
SNS = sympathetic nervous system  
  
Ongoing and Future Trials 
 
Heart Failure. The EMPA-TROPISM RCT is 
comparing the efficacy and safety of empagliflozin in non-
diabetic HF patients.30  The Empire HF trial will elucidate 
the effects and modes of action of empagliflozin in HFrEF 
patients with and without T2DM.31   
The EMPEROR trials will study the empagliflozin also 
in patients with HF without diabetes. The EMPEROR-
Reduced trial is enrolling ≈3600 patients with HFrEF 
(ejection fraction ≤ 40%), half of whom are expected not 
to have diabetes.32  The EMPEROR-Preserved trial is 
enrolling ≈5750 patients with HF with preserved ejection 
fraction (HFpEF) (ejection fraction >40%), with and 
without diabetes.33 The EMPERIAL-Preserved and 
EMPERIAL-Reduced are RCTs designed to investigate 
the effects of empagliflozin on exercise capacity and 
patient-reported outcomes in patients with chronic stable 
HFpEF and HFrEF, respectively. 34  
Coronary Artery Disease. The EMMY trial will test 
empagliflozin in patients with myocardial infarction 
regardless of their diabetic status. The EMMY trial will 
therefore explore the concept of SGLT2 inhibition to 
improve cardiac remodeling, pre-and after-load reduction 
and cardiac metabolism regardless of its antidiabetic 
effects.35   
Chronic Kidney Disease (CKD). The EMPA-REIN 
trial will examine the acute and chronic renal effects of 
empagliflozin in healthy volunteers.36  The DAPA-CKD 
trial will determine the efficacy and safety of dapagliflozin 
10 mg/d to delay the progression of kidney disease in 
patients with both diabetic and nondiabetic CKD.27  The 
DIAMOND trial will study the effects of dapagliflozin in 
non-diabetic patients with proteinuria  
Current clinical trial data do not support the use of 
SGLT-2 inhibitors in patients with eGFR <30 ml/min/1.73 
m2. Ongoing trials considering patients with CKD stage 4 
include EMPA-KIDNEY (empagliflozin), SCORED 
(Sotagliflozin; NCT03315143), and SOLOIST-WHF 
(Sotagliflozin; NCT03521934).37   
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